NCT04269811View on ClinicalTrials.gov

Flu-Bu-Mel Conditioning Regimen for Myeloid Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

January 15, 2020

Primary Completion Date

March 30, 2023

Study Completion Date

June 30, 2023

Conditions
Relapse Rate After Allo-HSCT
Interventions
DRUG

Flu-Bu-Mel

5-day fludarabine + 2-day busulfan (3.2mg/kg) + 2-day melphalan (50-70mg/m2)

Trial Locations (2)

200025

Blood & Marrow Transplantation Center, RuiJin Hospital, Shanghai

Unknown

Shanghai No6 Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Jiao Tong University School of Medicine

OTHER

NCT04269811 - Flu-Bu-Mel Conditioning Regimen for Myeloid Disease | Biotech Hunter | Biotech Hunter